Statement: Patients receiving intervention 1 of the primary trial undergo a 21 day treatment cycle, up to a total of 6 times, but will stop earlier if they suffer disease progression or unacceptable toxicity occurs.
Primary_evidence: INTERVENTION 1:    Arm I   Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.   ONTAK: Given IV   flow cytometry: Correlative studies   immunohistochemistry staining method: Correlative studies   enzyme-linked immunosorbent assay: Correlative studies   laboratory biomarker analysis: Correlative studies   protein expression analysis: Correlative studies